Karen Tsui1, Amar Gajjar1, Chenghong Li1, Deokumar Srivastava1, Alberto Broniscer1, Cynthia Wetmore1, Larry E Kun1, Thomas E Merchant1, David W Ellison1, Brent A Orr1, Frederick A Boop1, Paul Klimo1, Jordan Ross1, Leslie L Robison1, Gregory T Armstrong1. 1. Department of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee (K.T., A.B., A.G., C.W.); Department of Biostatistics, St Jude Children's Research Hospital, Memphis, Tennessee (C.L., D.S.); Department of Radiological Sciences, St Jude Children's Research Hospital, Memphis, Tennessee (L.E.K., T.E.M.); Department of Pathology, St Jude Children's Research Hospital, Memphis, Tennessee (D.W.E., B.A.O.); Department of Surgery, St Jude Children's Research Hospital, Memphis, Tennessee (F.A.B., P.K.); Semmes-Murphey Neurologic and Spine Institute, Memphis, Tennessee (F.A.B., P.K.); Department of Neurosurgery, University of Tennessee Health Science Center, Memphis, Tennessee (F.A.B., P.K.); University of Tennessee Health Science Center, College of Medicine, Memphis, Tennessee (J.R.); Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, Tennessee (L.L.R., G.T.A.).
Abstract
BACKGROUND: Multimodal therapy has improved survival for some childhood CNS tumors. However, whether risk for subsequent neoplasms (SNs) also increases is unknown. We report the cumulative incidence of, and risk factors for, SNs after a childhood primary CNS tumor and determine whether treatment that combines radiation therapy (RT) with chemotherapy increases risk for SNs. METHODS: Analyses included 2779 patients with a primary CNS tumor treated at St Jude Children's Research Hospital between 1985 and 2012. Cumulative incidence and standardized incidence ratios (SIRs) were estimated for SNs confirmed by pathology report. Cumulative incidence among the 237 five-year medulloblastoma survivors treated with multimodal therapy (RT + chemotherapy) was compared with a historical cohort of 139 five-year survivors treated with RT but no chemotherapy in the Childhood Cancer Survivor Study. RESULTS: Eighty-one survivors had 97 SNs. The cumulative incidence of first SN was 3.0% (95% CI: 2.3%-3.9%) at 10 years, and 6.0% (95% CI: 4.6%-7.7%) at 20 years from diagnosis. Risks were highest for subsequent glioma, all grades (SIR = 57.2; 95% CI: 36.2-85.8) and acute myeloid leukemia (SIR = 31.8; 95% CI: 10.2-74.1). Compared with RT alone, RT + chemotherapy did not increase risk for SNs (hazard ratio: 0.64; 95% CI: 0.38-1.06). Among five-year survivors of medulloblastoma treated with multimodal therapy, cumulative incidence of SN was 12.0% (95% CI: 6.4%-19.5%) at 20 years, no different than survivors treated with RT alone (11.3%, P = .44). CONCLUSION: The cumulative incidence of SNs continues to increase with time from treatment with no obvious plateau, but the risk does not appear to be higher after exposure to multimodal therapy compared with RT alone. Continued follow-up of survivors as they age is essential.
BACKGROUND: Multimodal therapy has improved survival for some childhood CNS tumors. However, whether risk for subsequent neoplasms (SNs) also increases is unknown. We report the cumulative incidence of, and risk factors for, SNs after a childhood primary CNS tumor and determine whether treatment that combines radiation therapy (RT) with chemotherapy increases risk for SNs. METHODS: Analyses included 2779 patients with a primary CNS tumor treated at St Jude Children's Research Hospital between 1985 and 2012. Cumulative incidence and standardized incidence ratios (SIRs) were estimated for SNs confirmed by pathology report. Cumulative incidence among the 237 five-year medulloblastoma survivors treated with multimodal therapy (RT + chemotherapy) was compared with a historical cohort of 139 five-year survivors treated with RT but no chemotherapy in the Childhood Cancer Survivor Study. RESULTS: Eighty-one survivors had 97 SNs. The cumulative incidence of first SN was 3.0% (95% CI: 2.3%-3.9%) at 10 years, and 6.0% (95% CI: 4.6%-7.7%) at 20 years from diagnosis. Risks were highest for subsequent glioma, all grades (SIR = 57.2; 95% CI: 36.2-85.8) and acute myeloid leukemia (SIR = 31.8; 95% CI: 10.2-74.1). Compared with RT alone, RT + chemotherapy did not increase risk for SNs (hazard ratio: 0.64; 95% CI: 0.38-1.06). Among five-year survivors of medulloblastoma treated with multimodal therapy, cumulative incidence of SN was 12.0% (95% CI: 6.4%-19.5%) at 20 years, no different than survivors treated with RT alone (11.3%, P = .44). CONCLUSION: The cumulative incidence of SNs continues to increase with time from treatment with no obvious plateau, but the risk does not appear to be higher after exposure to multimodal therapy compared with RT alone. Continued follow-up of survivors as they age is essential.
Authors: Aliki J Taylor; Mark P Little; David L Winter; Elaine Sugden; David W Ellison; Charles A Stiller; Marilyn Stovall; Clare Frobisher; Emma R Lancashire; Raoul C Reulen; Michael M Hawkins Journal: J Clin Oncol Date: 2010-11-15 Impact factor: 44.544
Authors: Wendy M Leisenring; Ann C Mertens; Gregory T Armstrong; Marilyn A Stovall; Joseph P Neglia; Jennifer Q Lanctot; John D Boice; John A Whitton; Yutaka Yasui Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544
Authors: M P Little; F de Vathaire; A Shamsaldin; O Oberlin; S Campbell; E Grimaud; J Chavaudra; R G Haylock; C R Muirhead Journal: Int J Cancer Date: 1998-10-29 Impact factor: 7.396
Authors: Stephen J Laughton; Thomas E Merchant; Charles A Sklar; Larry E Kun; Maryam Fouladi; Alberto Broniscer; E Brannon Morris; Robert P Sanders; Matthew J Krasin; John Shelso; Zang Xiong; Dana Wallace; Amar Gajjar Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544
Authors: Tara O Henderson; John Whitton; Marilyn Stovall; Ann C Mertens; Pauline Mitby; Debra Friedman; Louise C Strong; Sue Hammond; Joseph P Neglia; Anna T Meadows; Leslie Robison; Lisa Diller Journal: J Natl Cancer Inst Date: 2007-02-21 Impact factor: 11.816
Authors: Debra L Friedman; John Whitton; Wendy Leisenring; Ann C Mertens; Sue Hammond; Marilyn Stovall; Sarah S Donaldson; Anna T Meadows; Leslie L Robison; Joseph P Neglia Journal: J Natl Cancer Inst Date: 2010-07-15 Impact factor: 11.816
Authors: Gregory T Armstrong; Qi Liu; Yutaka Yasui; Sujuan Huang; Kirsten K Ness; Wendy Leisenring; Melissa M Hudson; Sarah S Donaldson; Allison A King; Marilyn Stovall; Kevin R Krull; Leslie L Robison; Roger J Packer Journal: J Natl Cancer Inst Date: 2009-06-17 Impact factor: 11.816
Authors: Ralph Salloum; Yan Chen; Yutaka Yasui; Roger Packer; Wendy Leisenring; Elizabeth Wells; Allison King; Rebecca Howell; Todd M Gibson; Kevin R Krull; Leslie L Robison; Kevin C Oeffinger; Maryam Fouladi; Gregory T Armstrong Journal: J Clin Oncol Date: 2019-02-07 Impact factor: 44.544
Authors: Tineke Boesten; Nicolas U Gerber; Daniela Kandels; Amedeo A Azizi; Rene Schmidt; Monika Warmuth-Metz; Torsten Pietsch; Rolf-Dieter Kortmann; Astrid Gnekow; Michael A Grotzer Journal: Neurooncol Pract Date: 2016-12-09
Authors: David Wallace; Douglas R Taylor; Haitao Pan; Scott Hwang; John T Lucas; Paul Klimo; Santhosh A Upadhyaya; Frederick A Boop Journal: Pediatr Blood Cancer Date: 2020-04-14 Impact factor: 3.167